Company: NIVFW
Filing Date: 2025-03-07
Form Type: F-1
Source: 0001213900-25-021404
Chunk: 124

Company: NewGenIvf Group Ltd
Filing Date: 2025-03-07
Form: F-1
Chunk 124
---
 treatment fees upon the completion of client’s treatment. Normally, agents provide potential clients’ contact information to the sales team of NewGenIvf, who then approach potential clients and provide consultation on services. Overall, approximately 50% of NewGenIvf’s patients are referrals from agents, among which approximately 80% are referrals from China and the remaining 20% from India, whereas the remaining 50% of NewGenIvf’s patients are patients who contact NewGenIvf directly through its websites from social media promotions. With its partnerships in various countries, NewGenIvf believes it is able to better benefit from the growing market opportunities. 87 Exclusively Owned and Licensed Technology for Family Planning and Access to Mature Fertility Technologies NewGenIvf believes that its licenses and/or access to mature technologies contribute to its ability to identify and tailor ARS services to individual patient’s needs. These technologies include:

| ● | Preimplantation Genetic Screening (“PGS”): PGS is                                                                                   
 used in parallel with an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too 
 few chromosomes) in a developing embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid   
 embryos that have a higher chance of implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf   
 by achieving a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%.                                           |

| ● | Next-Generation Sequencing (“NGS”): NGS is a high-throughput                                                                             
 technology for determining the sequence of deoxyribonucleic acid (“DNA”) or ribonucleic acid (“RNA”) to study                            
 genetic variation associated with diseases or other biological phenomena. NGS determines the sequence of a sample all at once by         
 using parallel sequencing. Traditional Sanger sequencing determines the sequence of a sample one section at a time. Sequencing thousands 
 of gene fragments simultaneously with NGS reduces time and cost associated with sequencing and increases the coverage quality and        
 data output.                                                                                                                             |

| ● | Preimplantation Genetic Diagnosis (“PGD”): Similar                                                                                    
 to PGS, PGD is also used in parallel with an IVF treatment cycle. But PGD is a process more enhanced than PGS since it scans for      
 individual genes. PGD is the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell